Anglesey Mining (LON: AYM) shares jumped 208.3% to 0.925p has entered into a binding letter of intent with largest shareholder Energold Minerals Inc that will enable a restructuring of the business and improve the balance sheet. Two of Anglesey Mining’s investments will be swapped for the elimination of £4m of debt. Energold Minerals is paying £350,000 for non-voting exchangeable warrants to provide immediate cash. The focus will be the Parys Mountain project. Energold Mining president Brendan Cahill and Jim Williams are joining the board.
Iodine producer Iofina (LON: IOF) has signed an agreement with Western Midstream Partners for the development of the next IOsorb plant in the Permian Basin between western Texas and southeastern New Mexico. The plant will be twice as large as existing plants with a capacity to process 50,000 barrels of brine water per day supplied by Western Midstream. It will cost up to $9m with annual production of up to 220 metric tonnes of iodine. It could be producing before the end of 2026. The share price gained 5.75% to 23p.
Stephen Wolstenhulme has a stake in ValiRx (LON: VAL) that is currently below 3%. The share price rose 4.29% to 0.365p.
Geospatial data software supplier 1Spatial (LON: SPA) has won a new contact for data transmission and integration for the National Underground Asset Register, which is operated by Ordnance Survey. The contract is worth £4.2m over two years. The share price improved 3.33% to 46.5p.
FALLERS
Shares in North Sea oil and gas company Deltic Energy (LON: DELT) have fallen a further 18.8% to 3.25p following the delay to the recommended a 7.46p/share bid from Rockrose Energy, which is owned by Viaro Energy. North Sea regulator NSTA wants further information in order to reach a decision to grant the change of control of licences. The long stop of the bid has been extended to the end of March 2026.
Pharmacogenetic testing company Genedrive (LON: GDR) doubled full year revenues to £1m. Cash has fallen from £1.2m at the end of June 2025 to £320,000 at the end of November 2025. The proposed £1m loan is still being negotiated. The share price dipped 5.13% to 0.925p.
Skin health treatments developer SkinBioTheapeutics (LON: SBTX) reported revenues 284% higher at £4.6m. The loss reduced from £2.95m to £715,000. There was £4.8m in the bank at the end of June 2025. Trading is in line with market expectations of 2025-26 revenues of £6.2m. New cosmetics products are being launched with Zenakine. The share price declined 376% to 16p.
Quantum Blockchain Technologies (LON: QBT) has entered into three non-disclosure agreements with ASIC manufacturers in relation to its Bitcoin mining technology. They have developed equipment that will be made available to QBT so that it can install and test its software. Another non-disclosure agreement has been signed with a Bitcoin mining pool. This could bypass the need to modify the operating system of mining machines using the pool. The share price slipped 3.33% to 0.725p.